

**Wanbury Limited**

**Regd. Office :** BSEL Tech Park, B-wing  
10<sup>th</sup> Floor, Sector-30 A,  
Opp. Vashi Railway Station,  
Vashi Navi Mumbai 400 703  
Maharashtra, INDIA  
Tel. : +91-22-6794 2222  
          +91-22-7196 3222  
Fax : +91-22-6794 2111/333  
CIN L51900MH1988PLC048455  
Email : info@wanbury.com  
Website : www.wanbury.com

November 15, 2024

To The Manager, Listing Departments, BSE Limited, P. J. Towers, Dalal Street, Mumbai – 400 001. <b>Scrip Code: 524212</b>	To, The Manager, Listing Department, National Stock Exchange of India Limited, Exchange Plaza, C - 1, Block- G, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051. <b>Symbol: WANBURY</b>
--	--

Dear Sir/Madam,

**Sub: Press release on Q2 & H1FY25 Financial Results**

Please find attached herewith copy of press release on Q2 & H1 FY25 Financial Results.

This is for your information and record.

Thanking you.

Yours faithfully,  
For Wanbury Ltd.

Jitendra J. Gandhi  
Company Secretary



Encl.: a/a.



## Q2 & H1 FY25 Earnings Release

*Q2 FY25 Revenue from operations stood at Rs.161.2 crore, up 11.6% Y-o-Y*

*Q2 FY25 EBITDA grew by 19.6% Y-o-Y to Rs.21.6 crore*

*Q2 FY25 PAT grew by 8.9% Y-o-Y to Rs.8.0 crore*

15<sup>th</sup> November, 2024, MUMBAI: Wanbury Ltd, a pharmaceutical company with a presence in the global API market and domestic branded formulations, has announced its financial results for the quarter and half year ended September 30, 2024.

### Consolidated Q2 FY25 Financial Highlights

Particulars (Rs. In Crore)	Q2 FY25	Q2 FY24	Y-o-Y	Q1 FY25*	Q-o-Q
Revenue from Operations	161.2	144.5	11.6%	131.1	22.9%
EBITDA (incl. other income)	21.6	18.1	19.6%	11.9	81.6%
EBITDA Margin (%)	13.4%	12.5%	89 bps	9.1%	433 bps
PAT	8.0	7.4	8.9%	1.0	672.8%
PAT Margin (%)	5.0%	5.1%	-13 bps	0.8%	418 bps

\*Note - The manufacturing facility at Patalganga was undergoing upgradation and renovation for part of the Q1FY25, and thus it was not utilized to its optimum levels, which impacted revenues and profitability for Q1FY25

### Financial Highlights

For the quarter ended as on 30<sup>th</sup> September 2024

- Revenue from operations stood at Rs. 161.2 crore in Q2 FY25, as against Rs. 144.5 crore in Q2 FY24, a growth of 11.6% on a year on year basis, driven by sales volume growth in key products like Metformin & Sertraline in API business and sales growth in Branded Formulation business.
- EBITDA Margins for Q2 FY25 stood at 13.4%
- EBITDA for the quarter is Rs. 21.6 crore as against Rs. 18.1 crore in Q2 FY24, a growth of 19.6% mainly on account of sales volume growth in key products like Metformin & Sertraline in API business and sales growth in Branded Formulation business.





### Key Highlights:

- For the third consecutive year, Wanbury's API manufacturing site in Patalganga won two safety awards at the Maharashtra Safety Awards Competition 2023, organized by the Maharashtra State Government, upholding its commitment to the highest safety standards
- Patalganga facility has received a USFDA Establishment Inspection Report (EIR) with a "No Action Indicated" (NAI) designation and zero 483 observations, confirming full compliance with regulatory standards

*Commenting on the performance, Mr. Mohan Rayana, Director of Wanbury Ltd., said, "Our quarterly performance demonstrates steady year-on-year growth, with revenue rising by 11.6% at Rs.161 crore and EBITDA by 19.6% at Rs.21.6 crore, driven by increased sales volumes in key API products such as Metformin and Sertraline, as well as growth in the Branded Formulation segment.*

*We continue to enhance our current API products by expanding capacity and geographic reach, with plans to accelerate growth by launching 3 new APIs in the near term. The Tanuku facility is currently undergoing a temporary shutdown for upgrades and further capacity expansion which will be completed shortly, allowing full operations to resume with improved productivity and cost efficiency from December 2024 onwards. Additionally, obtaining the Certificate of Suitability (CEP) for Dextromethorphan API from the European Directorate for the Quality of Medicines (EDQM) paves way for expansion into the European market.*

*Our commitment to safety and quality has been acknowledged with the Patalganga site receiving two safety awards for the third consecutive year.*

### Focus Area:

*Cost improvement through process engineering will continue to support the margin improvement.*

### About Wanbury Ltd.

Established in 1988, listed on the National Stock Exchange of India Ltd (Code: WANBURY) and BSE Ltd (Code: 524212). The company has a strong presence in API global market and domestic branded Formulation with its API being exported to over 50 countries and has Pan-India Formulation presence. The company has USFDA & EUGMP approved facilities at Tanuku (Andhra Pradesh) and Patalganga (Maharashtra).

The API product portfolio includes: Metformin, Sertraline, Tramadol, Diphenhydramine, Mefenamic acid, Paroxetine and various other products in pipeline. The company's clients include some of the leading global generic players.

In formulations, the Company has a wide presence across major therapeutic categories like, cough and cold solutions, gynaecology, orthopaedics, nutraceuticals, gastro intestinal, anti-inflammatory & analgesics.





For more details on Wanbury Ltd.: <https://www.wanbury.com/>

For further information please contact:

Jitendra J. Gandhi  
Company Secretary,  
Wanbury Limited  
BSEL Techpark, B' Wing, 10th Floor,  
Sector 30-A, Opp. Vashi Railway Station,  
Vashi, Navi Mumbai - 400703, India.  
Tel: +91-22-6794 2222  
Email: [jitendra.gandhi@wanbury.com](mailto:jitendra.gandhi@wanbury.com)

Hanishi Shah / Anand Venugopal  
Adfactors PR  
Oasis Complex, Kamala Mills  
Compound, City Hall, Pandurang  
Budhkar Marg, Lower Parel West,  
Mumbai - 400021  
Tel: +91 9619059339 / +91 7021852071  
Email: [hanishi.shah@adfactorspr.com](mailto:hanishi.shah@adfactorspr.com)  
[anand.venugopal@adfactorspr.com](mailto:anand.venugopal@adfactorspr.com)

**Disclaimer:**

*This document may contain statements which reflect management's current views and estimates and could be construed as forward-looking statements. The future involves certain risks and uncertainties and could cause actual results to differ materially from the current views being expressed. Potential risks and uncertainties include factors such as general economic conditions, foreign exchange fluctuation, pricing pressures, competition and regulatory developments.*

